GlassScriptPhysician profile
Maribeth Reid
NPI 1679088793
$1,133.84
in general payments reported to CMS, 2019-2025
11 companies · $40.84 in 2025
The $40.84 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $700 · 2022: $226 · 2023: $39.74 · 2024: $128 · 2025: $40.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $208.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $319.50 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $254.17 | 2021-2024 | Farxiga |
| Eisai INC. | $148.18 | 2021-2022 | |
| Glaxosmithkline, LLC. | $147.99 | 2021 | |
| Amgen INC. | $129.87 | 2024-2025 | Krystexxa, Repatha |
| Pfizer INC. | $39.71 | 2021 | |
| Alkermes, INC. | $25.03 | 2025 | Vivitrol |
| Abbott Laboratories | $22.05 | 2022 | |
| Neurocrine Biosciences, INC. | $19.89 | 2023 | Ingrezza |
| Allergan, INC. | $14.38 | 2021 | |
| Lilly USA, LLC | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maribeth Reid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.